Taihe Hospital

Running trials

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

  NCT07792954· Phase 3· Pfizer· Source

• Recruiting

  Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC

  NCT07741448· Phase 2· Zhiquan Hu· Source

• Not yet recruiting

  A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease

  NCT07677514· Phase 2· Jiangsu Carephar Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study of MI078 for Postpartum Depression

  NCT07721961· Phase 3· Nanjing Minova Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patients With ST-segment Elevation Myocardial Infarction

  NCT07587294· Renmin Hospital of Wuhan University· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

  NCT07378527· Phase 2/3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Recruiting

  A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

  NCT07303803· Phase 2· Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2

  NCT07263308· Phase 3· Capital Medical University· Source

• Recruiting

  A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

  NCT07282353· Phase 3· Cascade Pharmaceuticals, Inc· Source

• Not yet recruiting

  A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests

  NCT07087041· Beijing Friendship Hospital· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· BeOne Medicines· Source

• Active, not recruiting

  A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

  NCT06970743· Phase 3· BeOne Medicines· Source

• Recruiting

  A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

  NCT06413654· Phase 2/3· Shanghai Jiaolian Drug Research and Development Co., Ltd· Source

• Active, not recruiting

  Efficacy and Safety of Colchicine After PCI

  NCT06472908· Phase 3· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Active, not recruiting

  SIM0718 Treatment of Asthma Clinical Study

  NCT06488755· Phase 3· Simcere Pharmaceutical Co., Ltd· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

  NCT06420440· Phase 2· Chen Xiaoping· Source

• Active, not recruiting

  Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

  NCT06439576· Hoffmann-La Roche· Source

• Recruiting

  MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06345365· Phase 3· Zhongnan Hospital· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

  NCT06052059· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05528510· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Stroke2 recruiting
• Acute myeloid leukaemia1 recruiting
• Bladder cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic spontaneous urticaria1 recruiting
• Coronary artery disease1 recruiting
• Hepatitis B1 recruiting
• High blood pressure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Liver cirrhosis1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Obesity1 recruiting
• Primary biliary cholangitis1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

  NCT07357831· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites

  NCT06553456· Phase 2/3· Beijing Protgen Biotechnology Development Co., Ltd.· Source

• Completed

  Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

  NCT06353347· Phase 3· Shenzhen HighTide Biopharmaceutical Ltd.· Source

• Completed

  Head Position After Endovascular Therapy

  NCT06115707· Zhengzhou Yuan· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia

  NCT06355479· Phase 3· Healthgen Biotechnology Corp.· Source

• Completed

  Study on AI Recognition System Of Heart Sound In Congenital Heart Disease Screening

  NCT04307030· Xinhua Hospital, Shanghai Jiao Tong University School of Medicine· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Thymoma and thymic carcinoma4 works · 0 trials